revealed that leupeptin did not affect the Ii chain processing or the formation of stable class II dimers. The stimulatory effect of leupeptin observed on CII presentation suggests that leupeptin protects CII epitopes by interfering with proteases involved in the intracellular degradation of CII.
Introduction
MHC class I and II molecules bind peptide antigens and binding groove to allow the loading of antigenic peptides. The intracellular compartment where Ii chain is proteolytically present them to T cells (1-4). Whereas class I molecules predominantly bind peptides from cytosolic proteins before processed while class II molecules acquire antigenic peptide has been recently identified in B lymphoma cells (18) (19) (20) . their release from the endoplasmic reticulum (ER) (5,6), class II molecules present antigens that have access to This compartment is part of the endocytic pathway but differs from classical endosomes and lysosomes. the endocytic pathway (7-9). MHC class II molecules are expressed on the cell surface as heterodimers composed of The use of several metabolic inhibitors such as brefeldin A (BFA) and leupeptin has provided powerful tools for investiga-a 34 kDa α and a 28 kDa β chain (10). These αβ dimers associate in the ER with a third glycoprotein, the invariant (Ii) ting the molecular basis of antigen presentation. The fungal metabolite BFA inhibits the association of clathrin and γchain. The Ii chain has several functions in class II-restricted antigen presentation. First, it serves as a chaperone that adaptin with the membrane of the trans-Golgi network (TGN), thereby rapidly inducing the redistribution of the coat com-plays an essential role in the initial folding and oligomerization of newly synthesized α and β chains in the ER (11, 12) .
ponents from the Golgi membranes to the cytosol (21) . This drug can block the presentation of endogenous and Second, the Ii chain blocks the loading of peptides onto the class II molecules (13, 14) . Third, the Ii chain directs the exogenous antigens to MHC-restricted T cells by affecting the intracellular transport of newly synthesized MHC class I transport of class II molecules to an endosomal/lysosomal compartment (15) (16) (17) . Within the endocytic compartments, and class II molecules (22, 23) . Leupeptin is known to inhibit the MHC class II presentation pathway. It was reported to the Ii chain is degraded and removed from the class II slow the proteolysis of Ii and cause the accumulation of 21 25°C. The resulting digests were also used as a peptide mixture. and 12 kDa fragments (24) . This event impedes peptide binding and the subsequent conversion of class II dimers Production of I-A qϩ B lymphomas into a SDS-stable form (25) . The effect of leupeptin on antigen presentation may result from its action on processing enzymes
The B lymphoma cell lines M12 and A20 (H-2 d ) have been since this drug is an inhibitor of serine and thiol proteases, used previously as APC (31, 32) . Twenty million cells were such as cathepsins B and L (26) . fused with 10 8 total spleen cells from CII-primed DBA/1 mice We previously studied the conditions of presentation of type in the presence of 50% polyethylene glycol (mol. wt: 4000; II collagen (CII), a large fibrillar protein, which induces a Serva, Heidelberg, Germany) as previously described (33) . rheumatoid arthritis-like disease in H-2 q mice (27) . We pro-After hybridization, the cell suspensions were distributed into vided evidence that presentation of CII antigen requires microtiter plates (Costar, Cambridge, MA) at a concentration intracellular processing. However, efficiency of CII presentaof 2.5 ϫ 10 5 cells in 100 µl/well and selected for at least 3 tion is cell-type dependent. Presentation is markedly weeks in 10% FCS/complete medium supplemented with increased upon breakdown of the native molecule. We have 50 µM hypoxanthine and 40 µM azaserine (HA selection now further investigated the intracellular processing of CII in medium). The growing hybridomas were then cloned by A20 and M12 pre-B lymphoma cells, which are known to be limiting dilution (0.3 cells/well). Clones were screened by both very efficient professional antigen-presenting cells (APC), in the determination of I-A q molecules on the cell membrane a variety of experimental systems. For that purpose, we have and the efficiency of presenting CII to the T cell hybridomas generated hybrid A20 and M12 cells that express high levels as described below. of I-A q molecules. We show that these APC present CII when they have been pulsed with precleaved antigen. Treatment T cell hybridomas of hybrid M12 cells with BFA abrogates CII presentation to Three anti-CII T cell hybridomas (A2G10, A8E2 and A9E5) specific T cells. In contrast, leupeptin enhances CII presentawere used in this study. They were derived by fusion of tion but inhibits the I-A q -restricted recognition of ovalbumin. lymph node cells from CII-primed DBA/1 (H-2 q ) mice and the Our findings suggest that the increased presentation by BW5147 thymoma (mutant TCR αβ -). These T-T hybrids are leupeptin-treated APC is not linked to an alteration of I-A q -Ii CD4 ϩ and recognize CII when presented by I-A q molecules complex processing but rather results from leupeptin action (34) . As control, we used two anti-ovalbumin T cell hybridomas on the enzymes involved in the generation of the CII epitopes (a kind gift from J. Couderc, Institut Curie, Paris, France), one recognized by the CD4 ϩ T cell clones.
of which (clone 12A1.2.9) was restricted to I-A q molecules while the other (clone 3DO.11.10) was restricted to I-A d molecules. The T cell hybridomas were cultured in complete Methods medium (RPMI 1640 medium containing 5 ϫ 10 -5 M 2mercaptoethanol, 10 mM HEPES, 2 mM sodium pyruvate, Reagents and antibodies 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Ovalbumin (grade IV), chloroquine, BFA, leupeptin, antipain, glutamine) supplemented with 10% FCS. E64, pepstatin A, chymostatin, lipopolysaccharide (LPS) and FITC-conjugated anti-mouse Ig (M ϩ G ϩ A) were purchased Fixation procedure from Sigma (St Louis, MO). CTLA-4-Ig is a fusion protein APC were extensively washed with PBS and incubated with consisting of the extracellular portion of human CTLA-4 and 0.5% paraformaldehyde for 10 min at room temperature. an Ig C γ chain (28) . The following mAb, anti-I-A q,s,v , anti-I-A d , Fixed cells were then washed three times with RPMI 1640 anti-K q and anti-B7-1 (clone 1 G10), were obtained from medium supplemented with 40 mM HEPES and 5% FCS. PharMingen (San Diego, CA), and mAb MKD6 specific for I-A d molecules from M. Viguier (INSERM U152, Hô pital Cochin, Flow cytometric analysis Paris, France). The hybridoma cells M5/114 producing mAb to I-A d,q (ATCC, Rockville, MD; clone TIB120) were grown as
The cell surface markers were determined by an indirect ascites in nude mice. Purification of mAb from ascitic fluids immunofluorescence technique. Briefly, the cells were incubwas performed by a mAb trap kit Protein G (Pharmacia, ated 25 min at room temperature with an appropriate dilution Uppsala, Sweden). The Ii chain was detected using the antiof mAb in sodium azide-containing medium. After washes, a Ii chain cytoplasmic tail mAb IN1 (11).
FITC-or phycoerythrin (PE)-conjugated second-step reagent (species-specific antibodies) was added for 20 min at room Collagen preparations temperature. The cells were then washed and fixed with 1% formaldehyde (Sigma). Five thousand cells were analyzed Papain-solubilized CII, referred to as native CII, was purified from bovine nasal septum according to Lee-Own and with a cytofluorograph FACScan using Lysys software (Becton Dickinson, Mountain View, CA). For intracytoplasmic staining, Anderson (29) , dissolved in 0.05 M acetic acid (2 mg/ml) and stored at -80°C. Cyanogen bromide (CB) cleavage of CII was the cells were first fixed with 0.25% paraformaldehyde for 1 h, then incubated with 0.2% Tween 20 for 15 min at 37°C performed as described by Herbage et al. (30) and used as a mixture of CB peptides. The CB peptide mixture (5 mg and washed before addition of mAb (diluted in medium containing 0.2% Tween 20). In some experiments, B dissolved in 50 mM NH 4 HCO 3 ) was digested further with 50 µg of protease V8 from Staphylococcus aureus (endoproteinase lymphomas were stimulated with LPS (20 µg/ml) for 48 h at 37°C prior to FACS analysis. Glu-C; Boehringer, Mannheim, Meylan, France) for 15 h at Antigen-presentation assay Hybrid APC (10 5 cells/well) were irradiated (5,000 Rad) and co-cultured in flat-bottom microplates with T cell hybridomas (10 5 cells/well) in complete medium supplemented with 10% FCS in the presence of varying concentrations of antigen preparations. BFA treatment was performed for 15 min. After washing, the cells were pulsed for 4 h with the antigen. Chloroquine was added during the antigen pulse. Both BFA and chloroquine were washed out before addition of T cells. Leupeptin, antipain, E64, pepstatin A and chymostatin were added with the antigen and left in the culture during the presentation assay. Control cultures were performed in the presence of respective solvent only. After 24 h of incubation at 37°C, supernatants were transferred into new microplates and frozen at -20°C to lyse any remaining cells. Thawed supernatants were tested for their ability to support CTLL-2 proliferation assayed by [ 3 H]thymidine incorporation as previously described (27) . Results were expressed as mean of duplicates after deduction of mean background obtained by co-culture of T cells and APC without antigen (∆c.p.m.).
Radiolabeling and immunoprecipitation
For pulse-chase experiments, cells were incubated for 2 h in methionine-and cysteine-free RPMI 1640 supplemented with 5% dialyzed FCS. The cells were then centrifuged and resuspended in the same medium at 4ϫ10 7 cells/ml and metabolically labeled by a 20 min incubation with 1 mCi/ ml [ 35 S]methionine and [ 35 S]cysteine (Amersham, Les Ulis, France). After washings, the cells were either immediately lysed (no chase) or resuspended at 10 6 cells/ml in prewarmed RPMI 1640 containing 5% FCS and incubated for various periods of time at 37°C in a 5% CO 2 atmosphere. precleared lysates overnight with specific mAb (MKD6, M5/ 114 or IN1) in the presence of Protein G-Sepharose beads. After extensive washes in Tris-buffer saline (0.1% Triton X-100, 20 mM Tris-HCl, 150 mM NaCl, 0.05% NaN 3 , pH 7.5), clones of hybrid APC were selected for their high expression the material was eluted in Laemmli sample buffer containing of I-A q molecules and their potent capacity to stimulate T cell 2% SDS and either incubated for 1 h at room temperature or hybridomas specific for CII. In the present work, we used two boiled for 3 min. The immunoprecipitates were then subjected APC clones, M12.C10 and A20.3A2, as representative of the to 10-14% SDS-PAGE analysis and autoradiographed. Protein fusion with M12 and A20 lymphomas respectively. Cytosignals were quantitated on the autoradiographs using a fluorometric analysis was performed to determine the phenolaser scanner/densitometer apparatus (Applied Biosystems, typic profile of these APC. Figure 1 (A) exemplifies the results Weiterstadt, Germany). Treatment with leupeptin (1 mM) was obtained with the clone M12.C10 and shows that surface performed by including the inhibitor in the pulse and the expression of parental MHC class II molecules was remarkably chase media. strong on the hybrid APC. M12.C10 cells expressed slightly higher levels of I-A q than I-A d molecules, whereas it was the Results reverse situation for A20.3A2 cells. In addition, the staining of either MHC class II molecules with M5/114 mAb or the Ii Phenotypic analysis of hybrid APC chain with IN1 mAb was clearly positive in permeabilized M12.C10 cells (Fig. 1B) . Low levels of MHC class I and To induce the expression of I-A q molecules at the surface of the H-2 d B lymphomas, we have fused M12 and A20 cells surface Ig were detected on M12.C10 cells. Finally, M12.C10 cells showed little or no constitutive expression of the co-with DBA/1 spleen cells previously immunized with CII. Several Requirement for antigen breakdown and unfixed APC for presentation of CII by M12.C10 cells to specific T cell hybridoma A8E2. Irradiated M12.C10 cells (10 5 cells/well) were left untreated (j) or fixed with paraformaldehyde (s) and co-cultured with A8E2 T cell hybridoma (10 5 cells/well) for 24 h in the presence of various concentrations of antigen. Antigen preparations used were: native CII, the mixture of CB peptides and the further digests of CB peptides with V8 protease as indicated. Levels of IL-2 in the supernatants were then measured as described in Methods. Data are means Ϯ SEM of three independent experiments. stimulatory molecule B7-1 detected with a specific mAb or A q mAb (20 µg/ml) whereas it was unaffected by the same dose of anti-I-A d mAb (not shown). Collectively, our findings the mouse CTLA-4-Ig fusion protein (Fig. 1A) . However, B7-1 expression was induced on M12.C10 cells by activating show that the hybrid APC present antigens in an MHCrestricted T cell interaction and represent valuable tools for the cells with LPS (Fig. 1C) or with dibutyryl-cAMP (not shown). In contrast, A20.3A2 cells were B7-1 ϩ and this the study of intracellular processing of CII. expression was slightly increased upon activation of the cells CII presentation by B lymphomas requires antigen breakdown (data not shown). and intracellular processing M12.C10 hybrid cells were potent presenters for I-A qrestricted T cell clones specific for CII while exerting low As shown in Fig. 2, M12 .C10 cells pulsed with the native trihelicoidal form of CII failed to stimulate the T cell efficiency of presentation in the context of I-A d molecules. Moreover, the activation of T hybridoma A8E2 by antigen-hybridomas. This could be overcome by the use of CII precleaved with CB or digests of the mixture of CB peptides pulsed M12.C10 cells was blocked in the presence of anti-I-
BFA prevents presentation of CII epitopes
To investigate whether presentation of a fibrillar molecule, such as CII, required newly synthesized MHC class II molecules, we have tested the effect of BFA treatment of the APC on the T cell activation. Figure 3(A) shows that concentrations of BFA ranging from 1 to 10 µM completely abrogated the stimulation of A8E2 T cells. Detection of I-A q molecules at the cell surface of APC after the 4 h antigen pulse revealed that BFA did not alter the levels of class II expression ( Fig. 3B) . These data indicated that CII peptides are not presented by the recycling cell surface class II molecules.
Leupeptin enhances I-A q -restricted presentation of CII peptides
The processing events for CII presentation to T hybridomas were next determined by testing the effect of leupeptin. Treatment with this drug consistently enhanced the capacity of M12.C10 cells to present CII peptides to two different T cell hybridomas, A2G10 and A8E2 cells, and this effect was dose-dependent ( Fig. 4A) . The stimulating effect of leupeptin was not linked to an up-regulation of surface levels of either I-A q , B7-1 or B7-2 molecules (not shown). Interestingly, exposure of peritoneal macrophages or splenocytes to leupeptin reduced CII presentation while enhancing the presentation by immune B cells purified from the spleen of CII-primed mice or by hybrid B lymphoma M12.C10 (Fig. 4B ) and A20.3A2 (not shown). Thus, leupeptin-induced increase of T cell response was restricted to APC of B cell nature.
Ii chain processing and appearance of SDS-stable class II dimers are not affected by leupeptin
To investigate the mechanism of action of leupeptin in our attempts to immunoprecipitate selectively I-A q molecules with four different mAb not cross-reacting with I-A d were unsuccessful, we precleared I-A d molecules from the APC with MKD6 mAb and then precipitated the remaining I-A q by staphylococcal protease V8. The recognition of CII pepmolecules with anti-I-A d,q M5/114 mAb. The efficiency of tides by T cell hybridoma A8E2 was dependent on intracellular preclearing was attested by the complete loss of reactivity processing of the antigen since fixation of M12.C10 cells with when supernatants were reexposed to MKD6 mAb (not paraformaldehyde abrogated the T cell response to the CB shown). M5/114 immunoprecipitates were left for 1 h at room peptides of CII or the peptides generated by consecutive temperature before being subjected to SDS-PAGE. Similar treatment of CII with CNBr and V8 protease (Fig. 2) . The amounts of SDS-stable class II dimers were detected at 4 h requirement for intracellular degradation of CII in both hybrid of chase whether the cells were pretreated or not with APC was further demonstrated by experiments showing the leupeptin (Fig. 6 ). Densitometric scanning evaluation revealed dose-dependent inhibition of T cell responses in the presence that the intensity of the signal in leupeptin-treated cells was of the lysosomotropic agent, chloroquine (not shown). Ident-90% of control untreated cells. For unknown reasons, α and ical results were obtained when A20.3A2 cells were used as APC to stimulate A8E2 T cells (not shown).
β chains could not be detected at time 0 in untreated cells.
Leupeptin acts on proteases involved in the generation of to the MHC haplotype, we compared the ability of leupeptintreated hybrid APC to present epitopes from CII and from CII peptides ovalbumin, to specific I-A q -restricted T cell hybridomas. Expo-The lack of effect of leupeptin on MHC class II-Ii complexes sure of M12.C10 cells to leupeptin inhibited the presentation in M12.C10 cells suggested that the enhancing effect on CII of ovalbumin peptides to the 12A1.2.9 T cell hybridoma in a presentation was mediated through its action on serine and dose-dependent manner resulting in the complete abrogation thiol proteases, such as cathepsins B and L, influencing of the response at a concentration of 200 µg/ml (Table 1 ). In the generation of antigenic peptides from CII molecules.
contrast, the presentation of CII epitopes to specific A8E2 Therefore, we have investigated the effect of a panel of drugs hybridoma was increased by addition of leupeptin. Moreover, known to inhibit different cathepsins (35) . Addition of antipain leupeptin blocked the presentation of ovalbumin by M12.C10 or E64, two potent inhibitors of cathepsin B, induced the cells to an I-A d -restricted T cell hybridoma (Table 1) . These same enhancing effect as leupeptin on the presentation of findings strongly suggest that leupeptin protects CII epitopes CII peptides (Fig. 7A) . Pepstatin A, a strong inhibitor of by interfering with proteases involved in the intracellular cathepsin D, decreased the efficiency of CII presentation by degradation of CII. M12.C10 cells (Fig. 7B ). On the other hand, chymostatin, a weak inhibitor of cathepsins A, B and D, displayed a similar effect at high concentrations. However, like leupeptin, low Discussion concentrations of chymostatin increased the efficiency of CII presentation by M12.C10 cells.
The paucity of information on the processing of fibrillar molecules and the well-established arthritogenicity of CII in To ensure that the increased presentation mediated by leupeptin was related to the processing of the antigen and not H-2 q mice prompted us to examine the presentation of this fibrillar protein to specific T cells. Accordingly, we have the conformational structure of the native molecule accounts used B lymphoblasts known to be powerful APC in other for the poor uptake of CII by some APC, including B experimental systems antigens (36) and established hybrid lymphomas. Our data also provide evidence that once the clones of M12 or A20 cells that express high levels of I-A q CB peptides of CII have been internalized in the hybrid APC, molecules. The two representative clones selected, M12.C10 they undergo intracellular processing before their presentation and A20.3A2 cells, behave similarly in our experimental at the cell surface. This conclusion was inferred from the system despite slight differences in terms of phenotype and observations that the fixation of APC before an antigen pulse ability to stimulate the CII-specific T cell hybridomas. These or the presence of chloroquine during the culture period APC turned out to be potent presenters of CII provided that abrogated the stimulation of CII-specific T cell hybridomas the antigen was cleaved prior to its addition to the medium. similarly to other class II-restricted globular antigens. We had previously shown that the breakdown of CII was a
The inhibitory effects of chloroquine imply that the proteoprerequisite for an efficient presentation by other APC types, lysis of CII implicates the endosomal/lysosomal pathway. such as epidermal cells (27) . Thus, it can be assumed that Moreover, the fungal metabolite BFA which blocks protein transport, thereby impairing class I and class II antigen presentation (22, 23) , prevented the presentation of CII epitopes to T cell hybridomas. Thus, our results suggest that recycling MHC class II molecules are unlikely to present CII epitopes and that newly synthesized I-A q molecules bind CII peptides derived from the endocytic degradation of the antigen (37, 38) . In contrast to the inhibitory effect of chloroquine and BFA, leupeptin exhibits a strong and dose-dependent stimulating action. The leupeptin-mediated increase of antigen presentation is unusual since, in most of the cellular systems tested so far, the drug was found either to prevent or not affect T cell activation (35, 39, 40) . It was also reported (36) that presentation to anti-ovalbumin T-T hybridomas specific for epitopes poorly presented by a B cell hybrid was increased by the addition of leupeptin. Therefore, we were interested in analyzing the mechanisms of action of leupeptin in our experimental system. Increasing evidence has recently accumulated that leupeptin interferes with the MHC class II complex processing by slowing or blocking the degradation of the Ii chain and the appearance of SDS-resistant class II the drug. Two unusual observations seem to be peculiar to on the MHC haplotype but is related to the particular position of critical epitopes within the antigen since the presentation of ovalbumin by the same hybrid APC to I-A q -and to I-A d -References restricted T hybridomas was strongly inhibited. Interestingly, we have shown that treatment of macrophages or total spleen immunization (46,47). Thus, it is possible that macrophages
